Variables | Up to 1 Yr | After 1 Yr | ||||||
---|---|---|---|---|---|---|---|---|
Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||
HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
Age, yrs | 1.01 (0.99–1.04) | 0.20 | 1.00 (0.97–1.03) | 0.90 | 1.01 (0.98–1.05) | 0.47 | 1.01 (0.96–1.07) | 0.74 |
Sex | 0.85 (0.43–1.70) | 0.65 | 1.75 (0.59–5.24) | 0.32 | 1.32 (0.39–4.48) | 0.65 | 0.48 (0.11–2.00) | 0.31 |
Disease duration, yrs | 1.01 (0.98–1.03) | 0.69 | 1.01 (0.98–1.05) | 0.54 | 1.01 (0.98–1.05) | 0.44 | 1.02 (0.97–1.07) | 0.39 |
Stage | 0.91 (0.68–1.22) | 0.52 | 0.72 (0.47–1.10) | 0.13 | 1.36 (0.74–2.48) | 0.33 | 1.11 (0.49–2.52) | 0.80 |
Class | 1.10 (0.71–1.70) | 0.67 | 0.88 (0.49–1.55) | 0.65 | 0.84 (0.42–1.68) | 0.63 | 0.81 (0.31–2.11) | 0.67 |
Previous biologics | 1.73 (1.01–2.99) | < 0.05 | 2.50 (1.13–5.52) | < 0.05 | 1.43 (0.61–3.35) | 0.41 | 0.79 (0.19–3.29) | 0.75 |
Prednisolone use | 1.43 (0.79–2.59) | 0.23 | 1.55 (0.66–3.69) | 0.32 | 0.81 (0.31–2.11) | 0.67 | 1.56 (0.45–5.36) | 0.48 |
Methotrexate use | 0.55 (0.29–1.04) | 0.064 | 0.52 (0.22–1.21) | 0.13 | 0.89 (0.26–3.04) | 0.85 | 0.92 (0.18–4.79) | 0.92 |
DAS28-CRP | 1.05 (0.86–1.30) | 0.62 | 1.10 (0.82–1.49) | 0.52 | 1.07 (0.77–1.50) | 0.68 | 0.88 (0.53–1.46) | 0.61 |
HR and 95% CI for discontinuation of ADA were estimated with Cox proportional hazards regression analysis. ADA: adalimumab; DAS28-CRP: Disease Activity Score in 28 joints based on C-reactive protein.